Compare IPAR & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPAR | LIVN |
|---|---|---|
| Founded | 1982 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.5B |
| IPO Year | 1995 | 2015 |
| Metric | IPAR | LIVN |
|---|---|---|
| Price | $91.73 | $64.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $116.60 | $72.43 |
| AVG Volume (30 Days) | 223.0K | ★ 651.9K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | ★ 2.34 | N/A |
| EPS | ★ 5.24 | N/A |
| Revenue | ★ $1,317,700,000.00 | N/A |
| Revenue This Year | $3.86 | $9.79 |
| Revenue Next Year | $7.89 | $6.63 |
| P/E Ratio | $17.37 | ★ N/A |
| Revenue Growth | ★ 21.26 | N/A |
| 52 Week Low | $77.21 | $35.00 |
| 52 Week High | $142.50 | $71.58 |
| Indicator | IPAR | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 44.72 | 48.36 |
| Support Level | $87.60 | $61.63 |
| Resistance Level | $99.02 | $65.61 |
| Average True Range (ATR) | 2.84 | 1.94 |
| MACD | -0.11 | 0.05 |
| Stochastic Oscillator | 27.67 | 34.20 |
Interparfums Inc operates in the fragrance business and produces and distributes a wide array of prestige fragrance and fragrance-related products. It sells its product under the brand which includes Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lacoste, Lanvin, Moncler, Montblanc, Rochas and Van Cleef & Arpels. The company operates in two operating segments namely European based operations, SA, and United States based operations. The group sells its products to department stores, perfumeries, specialty stores, and domestic and international wholesalers and distributors.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.